Loading company…
Myrobalan Therapeutics develops oral therapies for brain dysfunction and central nervous system conditions.
Founded in Massachusetts in 2021 by Jing Wang, Zhigang He and Guoping Feng, Myrobalan Therapeutics develops oral neurorestorative therapies for brain and CNS conditions. Its pipeline includes a CSF1R inhibitor, a GPR17 antagonist, a TYK2 inhibitor and Program 4. In January 2024, the company raised USD 24 million in Series A funding led by Co-Win Ventures, with participation from Guan Zi Equity Investment Partnership, 3E Bioventures Capital and AB Magnitude Ventures Group.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in